The Neurochase team have delivered over 5000 catheter infusions to date in humans, have demonstrated neuro-restoration in Parkinson’s Disease in a phase 2 trial, and more than doubled progression free survival in the most devastating childhood brainstem cancer DIPG.

We provide expert consultancy to biotech and pharma - on direct delivery of therapies to the CNS. Our experience of catheter infusions to the CNS is unmatched.

Using our patent protected and licensable drug delivery strategies we can provide indication specific and tailored advice to practitioners looking to overcome the challenges of delivering therapies to the central nervous system.

For your Pre-clinical studies we can help you with protocol development for optimising drug distribution and conducting toxicology studies in validated preclinical models.

We can provide support with stereotactic equipment, devices and training to CRO's. We can also help with access to GLP facilities and Preclinical devices which are directly translatable to humans.

As you move to Clinical trial we can support protocol development, surgical workflow optimisation and surgeon training.

As of 2025 we will also be providing our revolutionary new Convection Enhanced Delivery (CED) devices which will bring dramatic improvements in the speed, safety and scalability of drug delivery procedures to the CNS.